TECLens, a company focused on eye care technology, has successfully secured $9.3 million in a Series A funding round. This investment was co-led by Johnson & Johnson Innovation (JJDC Inc.) and Yonjin Capital, along with support from Rimonci Capital and Sunmed Capital. The funds will help advance their new non-surgical method for correcting vision by reshaping the cornea using a technique called corneal cross-linking (CXL).
Unlike traditional CXL, which uses riboflavin and ultraviolet light to strengthen the cornea, TECLens has developed a unique approach called Quantitative Corneal Cross-Linking (qCXL). This method customizes the amount and pattern of UV light delivered based on a computational model specific to each patient’s eye. Their CXLens device comfortably tracks treatment in real-time, using an ultrasound sensor to maintain precision.
The CXLens device has shown promising results, particularly in treating keratoconus, and TECLens is now pushing forward with studies focused on correcting vision issues, especially presbyopia. Future applications might include treatments for conditions like pediatric myopia, low-order myopia, hyperopia, and astigmatism.
KEY QUOTES:
“We’re incredibly excited to garner investor support from both industry veterans and newcomers to the ophthalmology sector. This collective backing of our investors is a powerful endorsement of both our quantitative corneal cross-linking technology and our mission to deliver a non-invasive and cost-effective refractive treatment for millions of people with vision disorders. We’re honored by their support and view this as a strong validation of our innovative approach to addressing both refractive and therapeutic unmet needs in eye care.”
- Thomas Dunlap, CEO of TECLens
“The TECLens qCXL technology has tremendous potential to improve access to care for some of the world’s most complex vision correction needs, including presbyopia, keratoconus, low-order myopia, hyperopia, and astigmatism. TECLens’ approach to refractive correction is attractive to both patients and physicians and creates exciting possibilities for the future of the refractive market.”
- Dr. Roy Chuck, Chairman, Department of Ophthalmology, Montefiore Einstein and a pioneer of the foundational technologies behind TECLens
Source link
TECLens
